Physician profile

Steele B Tescher

Physician Assistant · Bismarck, ND

NPI 1851642847

$4,036.23

in general payments reported to CMS, 2019-2025

38 companies · $1,154 in 2025

The $1,154 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$3,434.52

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Dexcom, INC. $408.82 2022-2025 Dexcom G6 Transmitter
Abbvie INC. $356.48 2021-2025
Novartis Pharmaceuticals Corporation $303.72 2022-2025
Lilly USA, LLC $274.57 2022-2025 Mounjaro, Zepbound, Jardiance
Novo Nordisk INC $254.76 2022-2025 Rybelsus, Ozempic, Wegovy
Astrazeneca Pharmaceuticals LP $235.81 2023-2025 Airsupra, Breztri, Farxiga
Astellas Pharma US INC $211.97 2022-2025 Veozah, Myrbetriq
Amgen INC. $186.15 2023-2025 Evenity, Prolia, Tavneos
Abbott Laboratories $165.75 2022-2025 Freestyle Libre 3, Freestyle Libre 2
Pfizer INC. $154.50 2021-2025
Inspire Medical Systems, INC. $147.33 2023-2025 Inspire
Calliditas Therapeutics US INC. $140.40 2022-2025 Tarpeyo
Boehringer Ingelheim Pharmaceuticals, INC. $140.22 2022-2025 Jardiance, Tradjenta
Travere Therapeutics, INC. $131.48 2022-2024
E.R. Squibb & Sons, L.L.C. $94.44 2022-2025 Camzyos
Show all 38 companies
CompanyGeneral paymentsYearsTop products
Takeda Pharmaceuticals U.S.A., INC. $92.07 2025 Entyvio, Trintellix
Exact Sciences Corporation $65.60 2023-2025 Cologuard Collection Kit, The Cologuard Plus Collection Kit
Biohaven Pharmaceutical Holding Company LTD. $64.23 2022
Alexion Pharmaceuticals, INC. $59.47 2022-2023 Ultomiris
Daiichi Sankyo INC. $57.26 2022-2024 Injectafer
Vifor Pharma, INC. $50.18 2022-2023 Veltassa, Korsuva
Bayer Healthcare Pharmaceuticals INC. $48.35 2022-2023
Lexicon Pharmaceuticals, INC. $43.23 2023-2024 Inpefa
Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) $42.05 2025 Caplyta
Ardelyx, INC. $37.78 2024-2025 Ibsrela
Aurinia Pharma U.S., INC. $34.31 2022
Phathom Pharmaceuticals, INC. $28.98 2025 Voquezna
Axsome Therapeutics, INC. $28.25 2025 Auvelity
Xeris Pharmaceuticals, INC. $24.37 2021
Aimmune Therapeutics, INC. $23.29 2025 Zenpep
Genzyme Corporation $19.30 2022
Regeneron Healthcare Solutions, INC. $17.75 2025 Dupixent
Mallinckrodt Hospital Products INC. $16.74 2024 Acthar
Actelion Pharmaceuticals US, INC. $16.24 2024 Uptravi, Opsumit
Janssen Biotech, INC. $16.04 2025 Tremfya
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $15.56 2025 Xifaxan
Janssen Pharmaceuticals, INC $14.61 2023 Spravato
Otsuka America Pharmaceutical, INC. $14.17 2024 Jynarque

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Steele B Tescher

$4,036.23

in general payments reported 2019-2025

Years
2021-2025
Top company
Dexcom, INC.
Context
The $1,154 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).

https://glasscript.com/doctor/11094422/steele-b-tescher

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.